Misspelled Author Name and Funding Source.

Rui You,You‐Ping Liu,Ming‐Yuan Chen

DOI: https://doi.org/10.1001/jamaoncol.2020.7373

IF: 33.006

2021-01-01

JAMA Oncology

Abstract:did not choose concurrent chemotherapy plus radiotherapy in this study. 1Additionally, we have conducted a phase 2 prospective trial to evaluate the efficacy and safety of subsequent locoregional radiotherapy with concurrent programmed cell death protein 1 therapy in de novo metastatic nasopharyngeal carcinoma (ClinicalTrials.govidentifier: NCT04398056).We also thank Dr Sharma and colleagues for helping analyze the reasons for the positive results of the study.According to their first point, we agree that the improvement in overall survival could be mainly due to the prevention of local disease progression.However, we also observed that the number of cases with distant metastatic recurrence was 34 in the chemotherapy plus radiotherapy arm and 43 in the chemotherapyalone arm, which also showed that locoregional radiotherapy resulted in fewer distant metastatic recurrences (54.0%vs 68.3%). 1 The observation suggested a possible mechanism that targeting the index tumor lesion could delay the seeding of subsequent tumor clones at distant sites. 3Future work is needed to understand the mechanisms contributing to this observed synergy in the clinic.According to their second point, we observed that the percentage of patients who received subsequent chemotherapy was greater in the chemotherapy plus radiotherapy arm vs the chemotherapy-alone arm (36 of 37 [97%] vs 41 of 56 [73%]), 1 which showed that the survival benefit might be partially due to the increased percentage of patients receiving subsequent chemotherapy in the chemotherapy plus radiotherapy arm.The lower percentage of patients receiving subsequent chemotherapy in the chemotherapy-alone arm was attributed to 4 patients receiving salvage locoregional radiotherapy alone, more observed deaths prior to second-line therapy, and 31 of 56 patients (55.4%) with both locoregional and distant metastasis recurrence, among whom some patients refused further treatment.According to this point, we find that the prevention of local and distant disease progression and death due to the combined subsequent radiotherapy in the chemotherapy plus radiotherapy arm could further improve the tolerance and completion of second-line therapy.